War on Drugs, War on Doping? A Comparative Analysis and Its Policy Implications, key-note lecture by Paoli, Letizia
WAR ON DRUGS, WAR ON DOPING?  
A COMPARATIVE ANALYSIS  
AND ITS POLICY IMPLICATIONS 
Letizia Paoli 
University of Leuven, Faculty of Law  
 
1 
Conference:  “Evaluating the Unintended Effects of Anti-Doping” Aarhus University,  27-28 August, 2015  
The motivations of a comparison 
• Personal curiosity 
• Broader scientific and policy interest 
– Drug markets well studied, limited research on market  
for doping products (“doping market”) 
• Growing presence of underworld in sportsworld is feared 
– Avoid repeating war on drugs mistakes, inform 
development of better doping control policies  
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Data sources 
• More than twenty years of research on drug markets, 
organized crime and respective  control policies 
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Data sources 
• More than fifteen years of research on drug markets, 
organized crime and respective  control policies 
• Five years of research and three projects on doping 
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Data sources 
• More than fifteen years of research on drug markets, 
organized crime and respective  control policies 
• Five years of research and three projects on doping 
• Scientific and grey literature 
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Outline 
• Comparison of drugs/doping markets and policies on 
1. Products and their legal status 
2. Prevalence of their use 
3. Suppliers, including the latter’s background, motivations and 
modus operandi 
4. Distribution chains and the latter’s legal status 
5. Role of state agencies/representatives in market 
6. Control policies, including history, goals, justification and 
effectiveness  
• Conclusions and policy implications  
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1. Products and their legal status 
• Despite partial overlap of lists of prohibited substances, 
notable differences in core substances of two groups 
– Illegal drugs v. medicines 
Fully illegal v. quasi-illegal markets 
• Differences are decreasing due to expansion of internet 
exchanges and rise of “legal highs”/designer drugs 
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2. Prevalence of use 
• Paoli and Donati (2014)’s estimates of doping users in Italy:  
 
 
 
 
 
 
– Super elite athletes targeted by CONI/WADA account for 4% of 
doping athletes 
• Comparison with illegal drugs: Numbers of doping users 
– Higher or similar to heroin (98,000 users based on 0.25% past-
year prevalence rate or 218,000 opiate users needing treatment) 
– Much smaller than cocaine (353,000 users based on 0.9% rate) 
– Dramatically lower than cannabis (>2 million users per 5.2% rate)  
 
 
 
 
Users of all doping 
substances 
% of total 
Users w/o cannabis 
or cocaine 
% of total 
Athletes  185,000 73% 150,000 69% 
Body-builders 68,700 27% 68,700 31% 
Total 253,700 100% 218,700 100% 
Ranking of substances confirmed  
by US time series 
Prevalence of use of 
various drugs in 12th 
grade US students – 
Years 1991-2014 
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1991 1995 2000 2005 2010 2011 2012 2013 2014
Any illicit drug 29,40 39 40,9 38,4 38,3 40 39,7 40,1 38,7
Cannabis 23,9 34,7 36,5 33,6 34,8 36,4 36,4 36,4 35,1
Cocaine 3,5 4 5 5,1 2,9 2,9 2,7 2,6 2,6
Heroin 0,4 1,1 1,5 0,8 0,9 0,8 0,6 0,6 0,6
Steroids 1,4 1,5 1,7 1,5 1,5 1,2 1,3 1,5 1,5
0,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
40,00
45,00
Source: 
Monitoring the 
Future, 2015 
On the basis of archetypal profiles Paoli 
and Donati also (guess-)estimated usage 
Substance types Athletes Body-builders 
Total doses  
per type 
% of total 
Anabolic agents    45,304,348 173,522,903 218,827,251  58.93% 
Peptide  hormones, growth factors 
and related substances*, of which 
   19,956,522  3,767,419    23,723,941  6.39% 
- EPO 7,675,907 0 7,675,907 2,07% 
- GH** n.a. 3,564,001 3,767,419 0,96% 
- Chorionic Gonadotropin 12,280,615 203,418 12,484,033 3,36% 
Beta-2 agonists 13,130,435 11,081 13,141,515 3.54% 
Hormones and metabolic modulators 0 132,968 132,968 0.04% 
Diuretics and other masking agents 32,391,304 55,403 32,446,708  8.74% 
Stimulants 24,739,130 27,036,774 51,775,905  13.94% 
Narcotics       7,000,000  0       7,000,000 1.89% 
Glucocorticosteroids    21,130,435 531,871    21,662,306 5.83% 
Beta-blockers     2,608,696  0     2,608,696  0.70% 
Total doses 166,260,870  205,058,419  371,319,290    
Percent of total 44.78% 55.22% 100.0%   
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3. Suppliers 
• Italian doping suppliers (Paoli and Donati, 2014) are, 
unlike most drug dealers/traffickers, not marginalized: 
– Mostly Italian 
– Few have doping-related or other criminal records 
– Most have legitimate professions or occupations (see next) 
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Suppliers’ legitimate professions 
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Profession No. of 
suspects  
Gym owners or managers and body-building 
instructors 
158 
Veterinary physicians, breeders, horse drivers  140 
Owners/managers of dietary supplement 
shops  
64 
Pharmacists 20 
Physicians 17 
Staff members of cycling teams 12 
Sports federation officials 10 
Law enforcement and military staff 10 
Hospital employees  10 
Employees and salesmen of (para-) 
pharmaceutical companies 
6 
Staff of private security companies 2 
Leading relevant 
professions of the 
suspects reported 
in the NAS 
Investigation 
Database –  
1999-2011 
 
Source: Paoli and 
Donati, 2014 
3. Suppliers 
• Italian doping suppliers (Paoli and Donati, 2014) are, 
unlike most drug dealers/traffickers, not marginalized: 
– Mostly Italian 
– Few have doping-related or other criminal records 
– Most have legitimate professions or occupations (see next) 
– Very limited mafia involvement 
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Suppliers are mostly white-collar criminals 
Category Type 
Gym 
Gym managers or owners and body-building instructors  
Dietary supplement shop managers or owners 
Healthcare 
Pharmacists 
Physicians 
Hospital, health clinic and nursing home employees 
(Para-) pharmaceutical company employees or salesmen  
Organized  
sports 
Sports team staff members 
Sporting federation staff members 
Horseracing 
Veterinary physicians 
Breeders 
Drivers 
Semi-professional 
sportspeople 
Elite athletes, and their family members  
Hard-core body builders, including law enforcement, military 
and private security company staff,  and their family members  
Other Individuals without distinctive professions or occupations 
For sport-related categories, financial gain is not main aim 
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4. Distribution chains and their legal status 
• Illegal drug distributions chains are always illegal, 
doping chains are mostly not 
– No illegal market for doping methods 
– Most doping substances are produced “legally” and diverted 
at different stages from production sites to pharmacies 
Lower risks, lower profits 
• In both illegal drugs and doping markets users bypass 
domestic distribution chains with internet 
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Methods 
Sale, transfer, or administration of doping substance or method; 
 Money payment; Possible money payment 
Substances manufactured for doping purposes  
Actor committing crime; 
Pharmacist 
Intermediate 
supplier(s) User 
Substances manufactured for legitimate purposes by pharmaceutical companies 
Physician  
or other 
Users 
Producer of 
raw materials 
Distributor(s) 
Illegal lab 
Intermediate 
supplier(s) User 
Producer of 
raw materials 
Distributor(s) 
Trader 
Intermediate 
supplier(s) User 
Pharmaceutical 
company 
Distributor(s) 
Intermediate 
supplier(s) User 
Pharmaceutical 
company 
Distributor(s)/ 
transporter Truck robber 
Thief (hospital 
employee) 
Intermediate 
supplier(s) User 
Pharmaceutical 
company 
Distributor(s)/ 
transporter Hospital 
Intermediate 
supplier(s) User 
Pharmaceutical 
company 
Distributor(s)/ 
transporter Pharmacist 
Physician 
Intermediate 
supplier(s) User 
Pharmaceutical 
company 
Distributor(s)/ 
transporter Pharmacist 
Physician 
1. 
Legend:  
2a. 
2b. 
Actor unaware of committing crime; 
Possible actor; 
3a. 
3b. 
3c. 
3d. 
3e. 
Actor may/may not commit crime; 
5. Role of state agencies  
and representatives in market 
• Persistent involvement of state(-funded) sports bodies/ 
officials is most startling peculiarity of doping market 
– Mostly protectors/funders, occasionally also suppliers 
• No parallel in illegal drug markets of developed countries 
• No Italian specificity 
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Complemented by protection, tolerance and corruption  
of international  sports bodies 
6. Policies: Evolution and key components 
• International drug policy started to develop in 1900s, 
doping policy in 1960s 
• In drug policy, persistent focus on supply, in doping policy 
on athletes  
• In each, one pillar is predominant, with weaker others 
– In drug policy, repression  
– In doping policy, elite athletes testing 
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6. Policies: goals and justifications 
• Drug policy is aimed to reduce use of illegal drugs 
– Complemented with harm reduction since 1980s 
• Doping policy is aimed to both reduce harms of doping 
use and ensure respect of sport ethics 
– De facto focus on latter goal and elite athletes/competitions 
• In neither field, adequate justification of drugs/products 
prohibited 
• In neither field, systematic assessment of effectiveness or 
of perverse interactions between goals/pillars    
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6. Policy: Effectiveness? 
• Drugs: Growing evidence that repressive interventions 
are ineffective AND harmful 
– Treatment, harm reduction and some prevention interventions 
are effective 
• Doping: Contradictory data about athletes testing 
– Repression can deter white-collar suppliers and protectors 
– State funding also offers powerful leverage 
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Outline 
• Comparison of drugs/doping markets and policies on 
1. Products and their legal status 
2. Prevalence of their use 
3. Suppliers, including the latter’s background, motivations and 
modus operandi 
4. Distribution chains and the latter’s legal status 
5. Role of state agencies/representatives in market 
6. Control policies, including history, goals, justification and 
effectiveness  
 Conclusions and policy implications  
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Conclusions 
• Significant differences between two markets 
– Illegal v. quasi-illegal 
– Ordinary criminals v.  white-collar criminals 
– Role of state agencies and representatives in markets 
• Differences offer opportunities for doping control 
– E.g., repression and state funding   
• Common unclearness (and hypocrisy?) about policy goals, 
very limited policy evaluation 
– But supply-reduction cannot reduce availability or use 
25 
Policy implications 
• Legalize everything? 
• Not an option for many products, especially in doping 
• If legalization is chosen, many regulatory options 
– In most cases in combination with repression/illegal markets  
• Harm reduction could be key criterion for both policy fields 
26 
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What harm-reduction in anti-doping can entail: 
• Giving up idea of “doping-free” world 
• More thorough justification of product prohibitions 
• Legalization of least harmful products 
• Better information about harms to users 
• Shift from elite athletes to sportspeople 
• Protection of interests of non-doping athletes 
• Banning of other harmful practices in elite sports 
• Valuable metric for policy evaluation  
28 
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Thank you 
For questions: 
letizia.paoli@ 
law.kuleuven.be 
Backup slides 
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Paoli and Donati (2014) benefited from 
collaboration with Italian authorities 
• Drew on multiple data sources, largely from criminal justice 
system, i.e., Police Command for Health Protection (NAS) 
– Official documents of 46 anti-doping investigations 
– 80 data files on major NAS investigations from 1999 to 2009 
– Data on anti-doping activities of all 38 NAS Branch Offices 
– Seizure data from all police forces 
– Interviews with 26 NAS officers 
– Interviews with 7 prosecutors and 2 other experts 
– All relevant statistics, e.g., on sporting  and anti-doping testing in Italy 
– Scientific literature, grey literature, media reports, pharmacy price lists 
• Trianguated data to validate findings 
*“Comando Carabinieri per la Tutela della Salute” 
• Depict legal and policy environments, suppliers, and 
distribution chains 
• Develop market estimate, consisting of 
Paoli and Donati (2014) adopted “novel” 
market approach 
Numbers 
of 
users 
Total 
doses 
Market  
value 
Populations of 
sportspeople and 
other potential 
users 
Doses  
per 
user 
Publically 
available pricing 
data 
Anti-doping test 
results 
(CONI, CVD) 
and data on 
steroid use 
Expert knowledge 
of dosing 
practices and 
data on steroid 
use 
X = 
Price 
per 
dose 
X = 
Prevalence 
rates 
within 
populations 
X = 
Sporting 
statistics 
and gym 
data 
Market estimate can be framed in terms of 
users, usage, price, and value 
Numbers 
of 
users 
Total 
doses 
Market  
value 
Populations of 
sportspeople and 
other potential 
users 
Doses  
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Publically 
available pricing 
data 
Anti-doping test 
results 
(CONI, CVD) 
and data on 
steroid use 
Expert knowledge 
of dosing 
practices and 
data on steroid 
use 
X = 
Price 
per 
dose 
X = 
Prevalence 
rates 
within 
populations 
X = 
Sporting 
statistics 
and gym 
data 
Users Usage Price Value 
Users 
Potential users consist of sportspeople 
and “not-sportspeople” 
Category Notes Number 
Sportspeople Age 15+ 13,780,000 
• Competitive Referred to as “athletes” 4,690,000* 
- Elite athletes Competing nationally or 
internationally, as professionals or 
amateurs; Further distinguished as 
“super elite” athletes 
10,200** 
- Recreational athletes Competing sub-nationally Just < 4,690,000 
• Non-competitive Not referred to as “athletes”   
- Body-builders Largely affiliated with gyms 1,270,000*** 
- Other sportspeople Engage non-competitively in regular 
or occasional physical exercise 
7,820,000 
Not-sportspeople In rare instances, others age 15+ ≤ 40,000,000 
Sources: Istat (2007) for data on total and competitive sportspeople, except super elite athletes; Ministries of 
Sports and Social Solidarity for data pertaining to body-builders  
Notes: *unrounded figure is 4,685,257; **Super elite only, including some juveniles; ***Potential body 
builders, drawing on surveys of  gym attendance and availability of body-building equipment  
Anti-doping test results provide some insight to 
prevalence of use among athletes 
• Government agencies publish data on number and 
results of anti-doping tests of athletes 
– CONI* and sports federations test elite athletes 
– CVD** tests recreational athletes 
• Data have substantial shortcomings 
– Few out-of-competition tests 
• Elite athletes can anticipate tests 
• Recreational athletes might be less able to anticipate tests 
– Testing (urine) only addresses certain drugs 
– Evidence suggests non-trivial incidence of cheating 
*Italian National Olympic Committee 
**Commissione per la vigilanza e il controllo sul doping e per la tutela della salute nelle attività sportive 
Positive results serve as “lower bound” for 
calculating prevalence rates 
  2002 2003 2004 2005 2007 Avg 
Total tests  7,823 9,431 9,950 8,791 11,154 9,430 
Positive results 48 62 65 52 69 59 
% positive results 0.61 0.66 0.65 0.59 0.62 0.63 
Anti-doping test results for elite athletes, 2002-2007 
  
2003 2004 2005 2006 2007 2008 2009 2010 2011 
Avg 
2003-11 
Avg 
2008-11 
Total tests  740 1,556 1,875 1,511 1,607 955 1,328 1,115 1,676 1,303 1,374 
# of substances n.a. n.a. n.a. 40 52 n.a. 52 97 80 n.a. 76.3* 
Positive results 20 42 37 37 46 39 42 53 52 40.9          46.5          
% positive  2.7 2.7 2.0 2.4 2.9 4.1 3.2 4.8 3.1 3.4 3.8 
Anti-doping test results for recreational athletes, 2003-2011  
Source: CONI, 2012. 
Notes: CONI has published no data about positive results since 2007; 
in late 2012 it published data on adverse results. 
Source: Ministero della Salute and ISS; several years. 
Notes: *Average for 2007 and 2009-2011. 
CVD also reports results by substance type 
Substance types detected 2010 2011 
Anabolic agents 36 16 
Peptide hormones (growth 
factors) and related 
substances,* of which 
10 3 
- EPO 4 4 
- Chorionic gonadotropin 6 2 
Beta-2 agonists 6 4 
Hormones and metabolic 
modulators 
0 0 
Diuretics and other masking 
agents 
12 20 
Stimulants, of which  10 13 
- Cocaine 3 4 
Narcotics 2 0  
Cannabinoids 7 14 
Glucocorticosteroids 14 10 
Beta-blockers 0 0 
Total substances detected 97 80 
Source: our calculations on the basis 
of Ministero della salute (2011) and 
Ministero della Salute ( 2011) and 
Ministero della Salute and Istituto 
Superiore di Sanità (2012)  
*GH and other growth factors are not 
included as they were not detected in 
the urine tests ordered by CVD. 
Can use data to derive 
• numbers of users of 
doping substances in 
aggregate 
• numbers of users of 
particular substances 
Bottom line for athletes depends on treatment of 
cannabis and cocaine users 
Year 
Number 
of athletes 
% positive 
results on 
total tests w/ 
all substances 
(unrounded) 
Users of all 
doping 
substances 
% positive 
results on 
total tests 
w/o cannabis 
and cocaine 
(unrounded) 
Users of doping 
substances 
other than 
cannabis and 
cocaine 
2010 4,685,257 4.8 (4.75) 222,707 4.3 (4.26) 199,592 
2011 4,685,257 3.1 (3.10) 145,243 2.2 (2.20) 103,076 
Simple 
average 
4,685,257 - 183,975 - 151,334 
185,000 150,000 
Overall estimate of users accounts for 
bodybuilders but not others 
• Survey and investigative data yield rough estimate of 
number of body builders engaging in doping 
• Data not sufficient to yield compelling estimates of 
numbers of other potential users 
Users of all doping 
substances 
% of total 
Users w/o cannabis 
or cocaine 
% of total 
Athletes  185,000 73% 150,000 69% 
Body-builders 68,700 27% 68,700 31% 
Total 253,700 100% 218,700 100% 
Usage 
Doping doses for the main types  
of doping substances seized by NAS 
Doping substances 1 dose 
Anabolic agents 10 mg 
Peptide hormones, growth factors and related 
substances, of which 
  
-  EPO and other similar peptide hormones  200 IU or 1 mcg 
-  GH and other similar peptide hormones 1 IU or 0.333 mg 
-  Chorionic gonadotrophin 1,000 IU 
-  Gonadorelin 1.2 mg 
-  Adrenocorticotrophic hormone (ACTH)  
and other  corticotrophins 
0.25 mg 
- Insulin 10 IU 
Beta-2 agonists 2 mcg 
Hormones and metabolic modulators 10 mg 
Diuretics and other masking agents 25 mg 
Stimulants 25 mg 
Narcotics  50 mg 
Glucocorticosteroids 25 mg 
Beta-blockers 5 mg 
Archetypal profiles address differences in 
consumption patterns across sportspeople 
• Profiles normalized to 
– create representative athlete 
– create representative bodybuilder 
• Profiles framed in terms of standard doses for each 
substance (see back up) 
• Profiles conform to CVD detection shares for athletes 
and NAS seizure shares for bodybuilders 
Profiles have been “vetted” but methodology under review 
Steroids and body-builders account  
for lion’s share of doses 
Substance types Athletes Body-builders 
Total doses  
per type 
% of total 
Anabolic agents    45,304,348 173,522,903 218,827,251  58.93% 
Peptide  hormones, growth factors 
and related substances*, of which 
   19,956,522  3,767,419    23,723,941  6.39% 
- EPO 7,675,907 0 7,675,907 2,07% 
- GH** n.a. 3,564,001 3,767,419 0,96% 
- Chorionic Gonadotropin 12,280,615 203,418 12,484,033 3,36% 
Beta-2 agonists 13,130,435 11,081 13,141,515 3.54% 
Hormones and metabolic modulators 0 132,968 132,968 0.04% 
Diuretics and other masking agents 32,391,304 55,403 32,446,708  8.74% 
Stimulants 24,739,130 27,036,774 51,775,905  13.94% 
Narcotics       7,000,000  0       7,000,000 1.89% 
Glucocorticosteroids    21,130,435 531,871    21,662,306 5.83% 
Beta-blockers     2,608,696  0     2,608,696  0.70% 
Total doses 166,260,870  205,058,419  371,319,290    
Percent of total 44.78% 55.22% 100.0%   
Key 
substances are 
excluded  
for which 
there are clues 
of misuse: 
e.g., 
gonadorelin  
Region/Province Packages sold Total value 
 Packages sold 
per 100,000  
Total value 
per 100,000 
Piedmont 28,178 7,342,211 635.7 165,642 
- Novara province 4,063  1,113,759  1,184.4 324,673 
Aosta Valley 28 8,106 22.0 6,379 
Trentino Alto Adige 97 26,557 9.5 2,607 
Venetium 5,675 1,661,377 116.2 34,006 
Friuli 1,645 507,734 133.6 41,248 
Liguria 814 235,196 50.4 14,563 
Emilia Romagna 2,942 758,387 67.8 17,482 
- Ferrara province 2,396 623,474 669.3 174,164 
Tuscany 851 203,713 23.0 5,494 
Umbria 12 1,576 1.3 176 
Marche 867 242,723 55.2 15,464 
Latium 872 233,825 15.5 4,156 
Abruzzo 42 5,211 3.1 390 
Molise 401 147,955 125.0 46,121 
Campania   12,311        2,921,818  211.8 50,268 
- Salerno Province 6,207 1,508,804 561.2 136,408 
Apulia 157 35,247 3.4 864 
Basilicata 270 89,674 45.7 15,184 
Calabria 15,317 4,297,389 762.5 213,938 
- Cosenza province 7,049 2,024,430 961.0 275,993 
Sicilia 8,542 2,266,027 169.6 44,980 
- Caltanissetta province 2,583 748,339 948.6 274,833 
- Palermo province 5,406 1,393,428 434.3 111,951 
Sardegna 431 78,859 25.8 4,719 
Total 101,310 26,727,207 168.7 44,512 
Selected provinces and 
region 
            35,972 
(35.5%)  
  9,685,193 
(36.2%)  
674.5 181,616 
Rest of country            65,338  17,042,014  119.4 31,148 
Hypothetical sales in 
selected provinces and 
region at average rate 
  11,564    1,661,081 119.4 31,148 
Difference effective and 
hypothetical sales 
        24,408 
(24.1%)  
8,024,112 
(30.0%)  
n.a. n.a. 
Source: CVD, 2010 and Istat, for 
the population data. 
Price 
Pricing data drawn from official sources 
and internet 
• Most doping substances are sold in pharmacies and 
have “official” price, which is same throughout the 
country 
• For those that are not officially traded, i.e., no 
therapeutic purpose, internet websites provide some 
information 
Official prices may be too low or too high, but 
certainly not “right” 
Substance type 
Active 
ingredients per 
dose 
Average 
price per 
dose 
Anabolic agents (including 
testosterone) 
10 mg 1.12 
Peptide hormones, growth factors and 
related substances,* of which: 
Variable 4.76 
- EPO and other similar hormones  200 IU or 1 mcg 3.09 
- GH and other similar hormones 1 IU or 0.333 mg 13.90 
- Related substances**, of which Variable 2.50 
*Chorionic gonadotrophin 1,000 IU 3.27 
*Gonadorelin 1.2 mg 48.05 
*ACTH and other  corticotrophins 0.25 mg 3.70 
*Insulin 10 IU 0.03 
Beta-2 agonists 2 mcg 0.20 
Hormones and metabolic modulators 10 mg 1.26 
Diuretics and other masking agents 25 mg 0.40 
Stimulants 25 mg 0.60 
Narcotics 50 mg 1.28 
Glucocorticosteroids 25 mg 0.49 
Beta-blockers 5 mg 0.26 
Source: Our calculations on the basis of the Database on NAS investigations. 
• Prices in doping market may 
differ greatly from official prices 
- More in risky environments 
- More if other “service fees” 
included in net price 
- Less via internet 
• Official prices of doping doses 
are mostly cheaper than known 
prices of illegal drugs  
- Exceptions are GH and 
gonadorelin 
- By comparison, 0.25 gram 
doses of heroin and cocaine 
cost €10.49 and €17.29 and a 
hashish joint €3.73 
Value 
Market yields modest, but not 
insubstantial revenues 
• By multiplying official prices per dose with dosing estimates, we 
calculate annual retail revenues of €537 million 
– Steroids account for about €245 million or 46% of the total revenues, less 
than their share of doses (58.9%) due to relatively low prices 
– Peptide hormones account for disproportionately large share of revenue, 
i.e., 27% revenue v. 6% doses, due to relatively high prices 
• Estimate is, on most counts, very conservative 
– Reflects limits of testing and excludes GH and gonadorelin 
– Omits “other sportspeople” and “not-sportspeople” 
– Draws on official price data and does not account for other “service fees” 
• No information on manufacturers’ revenues or profits, as only one 
lab has been seized in Italy 
• Most other suppliers do not earn much 
– Few physicians serving elite athletes constitute exception 
How does doping market compare to those 
for traditional illegal drugs? 
• Numbers of users 
– Roughly similar to heroin (218,425 opiate users needing 
treatment) 
– Substantially smaller than cocaine (353,000 users based on 
0.9% prevalence rate) 
• Value of market 
– Substantially smaller than heroin and cocaine (€3,685 
million), on basis of “official” prices 
– Inattention to ‘risk premiums’ and other service charges 
may understate true value, though increasing use of 
internet might offset 
Effectiveness of drug policy 
• Growing evidence that repressive interventions are 
ineffective AND harmful 
– Prices of major drugs  decreased in most western countries 
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Long-term declines in heroin and 
cocaine prices in Europe … 
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Effectiveness of drug policy 
• Growing evidence that repressive interventions are 
ineffective AND harmful 
– Prices of major drugs  decreased in most western countries 
– Incarceration of users  causes great harm 
– Upstream interventions usually only provoke “balloon effect” 
– Market changes complicate supply reduction 
• Treatment, harm reduction and some prevention 
interventions are effective 
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Effectiveness of doping policy 
• Contradictory data about athletes testing 
– Focused on elite athletes, even if most harms are elsewhere   
– Despite considerable costs, very few positive samples 
– Evidence of changing attitudes and practices in elite cycling 
(Fincoeur, 2016), but not in very top cycling or other sports 
• Possible shift to more harmful substances/practices   
– Science constantly offer new doping opportunities 
• Repression can deter white-collar suppliers and protectors 
• State funding also offers powerful leverage 
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Harm assessment framework is publically 
available and in use* 
Identify possible harms and bearers 
(taxonomy) 
Rate 
severity 
of harm 
(scale) 
Establish causality of harm 
Rate 
incidence of 
criminal activity 
and of harm in 
relation to 
criminal activity 
(scale) 
Construct business model 
Prioritize harms 
(matrix) 
Evaluate severity and  
incidence of harm 
* Greenfield, V. and L. Paoli, 2013. A Framework  to Assess the Harms of Crimes, British J. of Criminology. 
Prioritization matrix combines 
severity and incidence scales 
Matrix of severity, incidence, and priorities 
SEVERITY INCIDENCE 
Always Persistently Occasionally Seldom Rarely 
Catastrophic H H H H/M M/H 
Grave H H H/M M/H M 
Serious H H/M M/H M L 
Moderate H/M M/H M L L 
Marginal M/H M L L L 
Source: authors based on Greenfield and Camm, 2005. 
Notes: H = Highest priority; M = Medium priority; L = Lowest priority; we use “non 
applicable” for harms that are irrelevant in a particular context. 
Matrix offers preliminary basis for addressing 
incommensurability, using quantitative and qualitative data 
First applications are promising* 
• Tested on cocaine trafficking and cannabis cultivation 
(and human trafficking) in Belgium and cocaine 
trafficking in The Netherlands 
• Findings are partially unexpected: 
– Harms of drug supply-side activities are lower in Belgium 
and Netherlands than often claimed 
– Only a small set of harms to individuals’ functional 
integrity and government’s reputation consistently score 
higher than low 
– Most supply-side harms arise from illegal status of drugs 
and enforcement practices 
 
 
* Paoli, L. et al. 2013. The Harms of Cocaine Trafficking. Journal of Drug Issues. 
Decorte, T. et al. 2014. Cannabis Production in Belgium. Gent: Academia Press. 
Identify possible harms and bearers 
Rate 
severity 
of harm 
Establish causality of harm 
Rate 
incidence 
Prioritize harms 
of criminal 
activity 
of harm in 
relation to 
criminal activity 
Step 1: Assess harms associated with supply-side activities 
Step 2: Assess current and proposed policy measures 
Practical path forward:  
Harms and policy assessment 
Evaluate net 
consequences of 
current and 
alternative 
policies 
Compare net 
consequences to 
implementation costs 
for each policy 
Compare  
results across  
policy options 
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Approach 
marries 
principles of 
harm reduction 
with those of 
risk 
assessment 
and enables 
baseline 
“estimation” of 
harms for 
policy 
evaluation 
